At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
Thomas Luechtefeld
Advertisement
Thomas Luechtefeld, PhD, is founder and CEO of Insilica.
Articles by Thomas Luechtefeld
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals
4
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
5